Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a research note published on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The company has a market cap of $833,000.00, a PE ratio of -0.01 and a beta of -0.90. Athersys has a fifty-two week low of $0.01 and a fifty-two week high of $1.99.

Athersys Company Profile

(Get Free Report)

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

See Also